BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Psoriatic arthritis clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for psoriatic arthritis: 66 (33 sponsors; 9 newly posted in the last 180 days, 1 stopped in the last 180 days; 3 new-entrant sponsors). Momentum score 31.8, rank 4 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 7, Phase 2 10, Phase 3 30, Phase 4 5, N/A 14.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Janssen Research & Development, LLC9P2 1, P3 5, P4 2, NA 112
Bristol-Myers Squibb BMY4P3 410
Takeda TAK4P3 410
AbbVie ABBV6P3 3, NA 2, P2 100
MoonLake Immunotherapeutics AG MLTX3P3 301
UCB Biopharma SRL4P1 2, P3 201
Amgen AMGN3P3 2, P1 111
Eli Lilly and Company LLY3P3 2, P4 100
Sun Pharmaceutical Industries Limited2P3 200
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.1P3 100
Jiangsu HengRui Medicine Co., Ltd.1P3 101
Suzhou Suncadia Biopharmaceuticals Co., Ltd.1P3 100
Novartis Pharmaceuticals NVS5P2 2, P1 1, NA 221
Adelphi Real World1NA 100
AndHealth1NA 100
CARE ARTHRITIS LTD.1P4 100
Celltrion1NA 101
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.1P2 100
Chongqing Genrix Biopharmaceutical Co., Ltd1NA 100
Clarent Biopharma, Inc. new entrant1P2 111
Dr. Reddy's Laboratories Limited, India new entrant1P1 111
Forward Therapeutics FWRD new entrant1P2 110
InventisBio Co., Ltd1P2 100
Janssen Pharmaceutica N.V., Belgium1NA 100
Janssen Scientific Affairs, LLC1NA 100

New-entrant sponsors: Clarent Biopharma, Inc., Dr. Reddy's Laboratories Limited, India, Forward Therapeutics.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-13 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT04957550 To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic ArthritisPsoriatic Arthritisactive not recruiting418
2027-02-17 est.P2Merck Sharp & Dohme LLC MRKNCT07486960 Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)Psoriatic Arthritisactive not recruiting140

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-31 est.P2Spyre Therapeutics, Inc. SYRENCT07148414 A Study of SPY072 in Rheumatic DiseaseRheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Rheumatic Diseases; Rheumatic Joactive not recruiting285
2026-09 est.P3AbbVie ABBVNCT06100744 A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) ReceiJuvenile Psoriatic Arthritisrecruiting40
2026-06-05P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06640257 A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic ArthritisPsoriatic Arthritisactive not recruiting208
2026-05-26P3UCB Biopharma SRLNCT04009499 A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisPsoriatic Arthritiscompleted1131

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "psoriatic arthritis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.